Çiğdem YÜCEL, Esin ÇALCI, Turan TURHAN, Burak TÜRKAY, Aydın ACAR

The importance of serum paraoxonase, arylesterase and ischemia modified albumin levels in evaluation of patients with Bell palsy

Objectives: This study aims to evaluate the possible roles of paraoxonase (PON), arylesterase (ARE), ischemia-modified albumin(IMA) and albumin-adjusted IMA levels in patients with Bell palsy.Patients and Methods: Thirty patients with Bell palsy and 30 healthy control subjects were included in the study. Serum PON, ARE,IMA, albumin-adjusted IMA and lipid profiles were measured.Results: Paraoxonase and ARE levels of the patient group were significantly lower than controls (p

PDF

___

1. Lalwani AK. Current Diagnosis & Treatment in Otolaryngology-Head & Neck Surgery. New York: McGraw-Hill; 2008. p. 885-930.
2. Gilden DH. Clinical practice. Bell’s Palsy. N Engl J Med 2004;351:1323-31.
3. Kucur C, Baştürk A, Gürsel AO. Bell paralizisi: Tanı, tedavi ve klinik takibi. Bakırköy Tıp Dergisi 2011;7:56- 9.
4. Yadav AS, Saini M. Evaluation of systemic antioxidant level and oxidative stress in relation to lifestyle and disease progression in asthmatic patients. J Med Biochem 2016;35:55-62.
5. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
6. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
7. Awadallah SM, Atoum MF, Nimer NA, Saleh SA. Ischemia modified albumin: an oxidative stress marker in b-thalassemia major. Clin Chim Acta 2012;41:907-10.
8. Liyan C, Jie Z, Yonghua W, Xiaozhou H. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008;22:45-9.
9. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-38.
10. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
11. Bar-Or D, Lau E, Winkler JV. A novel assay for cobaltalbumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5.
12. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261-2.
13. Cokluk E, Sekeroglu MR, Aslan M, Balahoroglu R, Bilgili SG, Huyut Z. Determining oxidant and antioxidant status in patients with genital warts. Redox Rep 2015;20:210-4.
14. Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme?. Med Clin (Barc) 2003;121:537- 48. [Abstract]
15. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2881-91.
16. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.
17. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113-4.
18. Türedi S, Karahan SC, Menteşe A, Gündüz A, Topbaş M, Koşucu P, et al. Investigation of relationship between the D-dimer and ischemia-modified albumin levels with the radiological imaging-based pulmonary embolism severity score in acute pulmonary embolism. Anadolu Kardiyol Derg 2010;10:346-52.